This condition is often seen in obese individuals and can contribute to overeating and weight gain
showed that ROS can increase the activity of gelatin-soluble matrix metalloproteinases (MMPs) and stimulate the secretion of pro-inflammatory cytokines (IL-1, IL-6, etc.) from human periodontal ligament fibroblasts (HPDLFs), thereby aggravating the destruction of periodontal tissue (62)
This step is not required for every drug
(Article in Japanese) Adachi T, Fujioka S, Shimomura Y, et al
Further experiments involving conditional ablation of the glucose transporter GLUT1 resulted in progressive myelin loss in vivo, without overt axonal pathology or behavioral deficits
Yes, GLP-1 medications commonly cause changes in bowel movements, though the nature and severity of these changes vary significantly among patients